⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 10, 2024Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial

Heng Xiang Kehui Meng Mei-Yu Wu Chongqing Tan

View Full Paper

Ask AI

Bookmark

Share

Abstract

In the ASTRUM-004 trial, serplulimab plus chemotherapy demonstrated significantly improved survival and controllable safety. This study assessed the cost-effectiveness of serplulimab plus chemotherapy in advanced squamous non-small cell lung cancer (sqNSCLC), considering the perspective of the Chinese healthcare system.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xiang et al. (2024) studied this question.

synapsesocial.com/papers/68e60bf4b6db64358759f207 https://doi.org/10.1080/14737167.2024.2379600

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients2024 · 4 citations
2Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in china: an external validation of ASTRUM-005 trialHuman Clinical Trial · 2026
3First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis2024 · 2 citations
4First-Line Serplulimab in Extensive-Stage Small Cell Lung CancerRCT · 2026 · 3 citations
5First-line serplulimab for locally advanced or metastatic squamous non–small cell lung cancer: Updated survival from the ASTRUM-004R trial.Human Clinical Trial · 2026